REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo shows promise for tough brain cancer
Disease control Recruiting nowThis study tests an experimental oral drug called emavusertib (CA-4948), taken alone or with another drug (ibrutinib), in adults with a rare brain lymphoma that has returned or not responded to prior therapy. The goal is to find safe doses and see if the combination can shrink tu…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated May 17, 2026 07:53 UTC
-
New drug cocktail takes on recurrent brain cancer
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has come back or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is t…
Matched conditions: REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:15 UTC